Does Rallies show 13F holders for ALZN?

Yes. Rallies tracks hedge fund and 13F ownership data for ALZN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ALZN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALZN. It does not provide personalized investment advice.

ALZN (Alzamend Neuro, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Alzamend Neuro, Inc. Common Stock (ALZN) is a publicly traded Healthcare sector company. As of May 21, 2026, ALZN trades at $1.24 with a market cap of $3.88M and a P/E ratio of -0.09. ALZN moved +23.76% today. Year to date, ALZN is -41.46%; over the trailing twelve months it is -65.91%. Its 52-week range spans $0.84 to $17.10. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces ALZN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ALZN stock?

Hedge funds tracked by Rallies that own ALZN include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Alzamend Neuro, Inc. Common Stock.

ALZN Key Metrics

Key financial metrics for ALZN
Metric	Value
Price	$1.24
Market Cap	$3.88M
P/E Ratio	-0.09
EPS	$-11.32
Dividend Yield	0.00%
52-Week High	$17.10
52-Week Low	$0.84
Volume	167.39K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$4.50M
Gross Margin	0.00%

Top Hedge Funds Holding ALZN

Renaissance Technologies holds 15.00K shares of ALZN, changed -23.82% as of Dec 31, 2024.

Latest ALZN News

Alzamend’s AL001 Reduces Myo-Inositol in 17 of 18 Regions, Spares Glutamate — Apr 7, 2026
Alzamend Neuro's AL001 Shows 7.8% Higher Brain Lithium Delivery, Faster 6.7h Uptake — Mar 26, 2026
Alzamend Neuro Launches Phase II Crossover Trial of AL001 vs Lithium Carbonate — Mar 16, 2026

Recent ALZN Insider Trades

AULT MILTON C III bought 108.39K (~$108.90K) on Apr 14, 2026.
AULT MILTON C III sold 1.85K (~$3.83K) on Dec 23, 2025.
Horne William B. sold 3.33K (~$7.06K) on Dec 19, 2025.

ALZN Analyst Consensus

1 analysts cover ALZN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.

Common questions about ALZN

Who owns ALZN stock?: Hedge funds tracked by Rallies that own ALZN include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Alzamend Neuro, Inc. Common Stock.
Does Rallies show 13F holders for ALZN?: Yes. Rallies tracks hedge fund and 13F ownership data for ALZN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ALZN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALZN. It does not provide personalized investment advice.